Clinical Feasibility of Ultrafast Contrast-Enhanced T1-Weighted 3D-EPI for Evaluating Intracranial Enhancing Lesions in Oncology Patients: Comparison with Standard 3D MPRAGE Sequence

References

1. 1.↵
   1. Kaal EC,
   2. Niël CG,
   3. Vecht CJ

   . Therapeutic management of brain metastasis. Lancet Neurol 2005;4:289–98 doi:10.1016/S1474-4422(05)70072-7 pmid:15847842

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Ranjan T,
   2. Abrey LE

   . Current management of metastatic brain disease. Neurotherapeutics 2009;6:598–603 doi:10.1016/j.nurt.2009.04.012 pmid:19560748

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Sperduto PW,
   2. Kased N,
   3. Roberge D, et al

   . Summary report on the graded prognostic assessment: an accurate and facile diagnosis specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012;30:419–25 doi:10.1200/JCO.2011.38.0527 pmid:22203767

   Abstract/FREE Full Text
4. 4.↵
   1. Sze G,
   2. Milano E,
   3. Johnson C, et al

   . Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. AJNR Am J Neuroradiol 1990;11:785–91 pmid:2114769

   Abstract/FREE Full Text
5. 5.↵
   1. Davis PC,
   2. Hudgins PA,
   3. Peterman SB, et al

   . Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. AJNR Am J Neuroradiol 1991;12:293–300 pmid:1902031

   Abstract/FREE Full Text
6. 6.↵
   1. Schellinger PD,
   2. Meinck HM,
   3. Thron A

   . Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999;44:275–81 doi:10.1023/a:1006308808769 pmid:10720207

   CrossRefPubMed
7. 7.↵
   1. Mugler JP,
   2. Brookeman JR

   . Three-dimensional magnetization-prepared rapid gradient-echo imaging (3D MPRAGE). Magn Reson Med 1990;15:152–57 doi:10.1002/mrm.1910150117 pmid:2374495

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Ellingson BM,
   2. Bendszus M,
   3. Boxerman J, et al

   ; Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neuro Oncol 2015;17:1188–98 doi:10.1093/neuonc/nov095 pmid:26250565

   CrossRefPubMed
9. 9.↵
   1. Kaufmann TJ,
   2. Smits M,
   3. Boxerman J, et al

   . Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro Oncol 2020;22:757–72 doi:10.1093/neuonc/noaa030 pmid:32048719

   CrossRefPubMed
10. 10.↵
    1. Kakeda S,
    2. Korogi Y,
    3. Hiai Y, et al

    . Detection of brain metastasis at 3T: comparison among SE, IR-FSE and 3D-GRE sequences. Eur Radiol 2007;17:2345–51 doi:10.1093/neuonc/noaa030 pmid:32048719

    CrossRefPubMed
11. 11.↵
    1. Norbeck O,
    2. Sprenger T,
    3. Avventi E, et al

    . Optimizing 3D EPI for rapid T1-weighted imaging. Magn Reson Med 2020;84:1441–55 doi:10.1002/mrm.28222 pmid:32112447

    CrossRefPubMed
12. 12.↵
    1. Likert R

    . A technique for the measurement of attitudes. Archives of Psychology 1932;22:1–55
13. 13.↵
    1. Koo TK,
    2. Li MY

    . A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 2016;15:155–63 doi:10.1016/j.jcm.2016.02.012 pmid:27330520

    CrossRefPubMed
14. 14.↵
    1. Landis JR,
    2. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74 doi:10.2307/2529310 pmid:843571

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Viera AJ,
    2. Garrett JM

    . Understanding interobserver agreement: the kappa statistic. Fam Med 2005;37:360–63 pmid:15883903

    PubMedWeb of Science
16. 16.↵
    1. Feinstein AR,
    2. Cicchetti DV

    . High agreement but low kappa, I: the problems of two paradoxes. J Clin Epidemiol 1990;43:543–49 doi:10.1016/0895-4356(90)90158-L pmid:2348207

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Mugler JP

    . Optimized three-dimensional fast-spin-echo MRI. J Magn Reson Imaging 2014;39:745–67 doi:10.1002/jmri.24542 pmid:24399498

    CrossRefPubMed
18. 18.↵
    1. Havsteen I,
    2. Ohlhues A,
    3. Madsen KH, et al

    . Are movement artifacts in magnetic resonance imaging a real problem? A narrative review. Front Neurol 2017;8:232 doi:10.3389/fneur.2017.00232 pmid:28611728

    CrossRefPubMed
19. 19.↵
    1. Munn Z,
    2. Pearson A,
    3. Jordan Z, et al

    . Patient anxiety and satisfaction in a magnetic resonance imaging department: initial results from an action research study. J Med Imaging Radiat Sci 2015;46:23–29 doi:10.1016/j.jmir.2014.07.006 pmid:31052060

    CrossRefPubMed
20. 20.↵
    1. Goncalves Filho AL,
    2. Conklin J,
    3. Longo MG, et al

    . Accelerated post-contrast wave-CAIPI T1 SPACE achieves equivalent diagnostic performance compared with standard T1 SPACE for the detection of brain metastases in clinical 3T MRI. Front Neurol 2020;11:587327 doi:10.3389/fneur.2020.587327 pmid:33193054

    CrossRefPubMed
21. 21.↵
    1. Mugler JP 3rd.,
    2. Brookeman JR

    . Theoretical analysis of gadopentetate dimeglumine enhancement in T1-weighted imaging of the brain: comparison of two-dimensional spin-echo and three-dimensional gradient-echo sequences. J Magn Reson Imaging 1993;3:761–69 doi:10.1002/jmri.1880030512 pmid:8400563

    CrossRefPubMed
22. 22.↵
    1. Komada T,
    2. Naganawa S,
    3. Ogawa H, et al

    . Contrast-enhanced MR imaging of metastatic brain tumor at 3 Tesla: utility of T(1)-weighted SPACE compared with 2D spin echo and 3D gradient echo sequence. Magn Reson Med Sci 2008;7:13–21 doi:10.2463/mrms.7.13 pmid:18460844

    CrossRefPubMed
23. 23.↵
    1. Kammer N,
    2. Coppenrath E,
    3. Treitl K, et al

    . Comparison of contrast-enhanced modified T1-weighted 3D TSE black-blood and 3D MPRAGE sequences for the detection of cerebral metastases and brain tumours. Eur Radiol 2016;26:1818–25 doi:10.1007/s00330-015-3975-x pmid:26334511

    CrossRefPubMed